GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for the new drug application (NDA) for Lamictal®XR™ (lamotrigine) Extended-Release Tablets.
This decision does not affect the current formulation of Lamictal® (lamotrigine) Tablets, which remains an important treatment for many patients with epilepsy.
Lamictal XR is an investigational once-daily extended-release formulation. The current marketed immediate-release formulation of Lamictal is twice daily for most patients with epilepsy. GSK is committed to working with the FDA to address any questions they have and evaluate the best way forward.
- « Epilepsy :: Study of New Epilepsy Treatment Underway at URMC
- Epilepsy :: Research shows how genetic mutation causes epilepsy in infants »
Sub-editorEpilepsy :: GSK’s Lamictal extended-release tablets for epilepsy
by Sub-editor ( Author at Spirit India )
Posted on September 26th, 2007 at 12:16 am.
Find more from SpiritIndia on: Epilepsy